These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 36136143)
1. Expression of nectin-4 in papillary renal cell carcinoma. Zschäbitz S; Mikuteit M; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Duensing S; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Erlmeier F; Steffens S Discov Oncol; 2022 Sep; 13(1):90. PubMed ID: 36136143 [TBL] [Abstract][Full Text] [Related]
2. Expression of Nectin-4 in Chromophobe Renal Cell Carcinoma in a Multicenter Cohort: Early Prognostic and Therapeutic Considerations. Mikuteit M; Zschäbitz S; Autenrieth M; Weichert W; Hartmann A; Steffens S; Erlmeier F Oncology; 2024; 102(6):503-509. PubMed ID: 38043528 [TBL] [Abstract][Full Text] [Related]
3. The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma. Mondorf Y; Mikuteit M; Ivanyi P; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief CG; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Steffens S; Erlmeier F Urol Int; 2022; 106(11):1168-1176. PubMed ID: 35654002 [TBL] [Abstract][Full Text] [Related]
4. Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort. Zschäbitz S; Erlmeier F; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Mondorf Y; Hartmann A; Ivanyi P; Steffens S J Cancer; 2022; 13(6):1706-1712. PubMed ID: 35399715 [TBL] [Abstract][Full Text] [Related]
5. cMET: a prognostic marker in papillary renal cell carcinoma? Erlmeier F; Bruecher B; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Mondorf Y; Ivanyi P; Mikuteit M; Steffens S; Hum Pathol; 2022 Mar; 121():1-10. PubMed ID: 34998840 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma. Mikuteit M; Zschäbitz S; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Duensing S; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos F; Walter B; Otto W; Burger M; Erlmeier M; Schrader AJ; Hartmann A; Erlmeier F; Steffens S; Urol Int; 2023; 107(7):713-722. PubMed ID: 37348477 [TBL] [Abstract][Full Text] [Related]
7. Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study. Erlmeier F; Steffens S; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Ivanyi P; Clin Genitourin Cancer; 2021 Feb; 19(1):53-59.e1. PubMed ID: 32778505 [TBL] [Abstract][Full Text] [Related]
8. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance. Klümper N; Ralser DJ; Ellinger J; Roghmann F; Albrecht J; Below E; Alajati A; Sikic D; Breyer J; Bolenz C; Zengerling F; Erben P; Schwamborn K; Wirtz RM; Horn T; Nagy D; Toma M; Kristiansen G; Büttner T; Hahn O; Grünwald V; Darr C; Erne E; Rausch S; Bedke J; Schlack K; Abbas M; Zschäbitz S; Schwab C; Mustea A; Adam P; Manseck A; Wullich B; Ritter M; Hartmann A; Gschwend J; Weichert W; Erlmeier F; Hölzel M; Eckstein M Clin Cancer Res; 2023 Apr; 29(8):1496-1505. PubMed ID: 36534531 [TBL] [Abstract][Full Text] [Related]
9. The prognostic impact of Claudin 6 in papillary renal cell carcinoma. Mikuteit M; Zschäbitz S; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Steffens S; Erlmeier F Pathol Res Pract; 2022 Mar; 231():153802. PubMed ID: 35180650 [TBL] [Abstract][Full Text] [Related]
10. Nectin-4 is widely expressed in head and neck squamous cell carcinoma. Sanders C; Lau JF; Dietrich D; Strieth S; Brossart P; Kristiansen G Oncotarget; 2022 Oct; 13():1166-1173. PubMed ID: 36268557 [TBL] [Abstract][Full Text] [Related]
12. Lymphangiogenesis in kidney cancer: expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma. Bierer S; Herrmann E; Köpke T; Neumann J; Eltze E; Hertle L; Wülfing C Oncol Rep; 2008 Oct; 20(4):721-5. PubMed ID: 18813809 [TBL] [Abstract][Full Text] [Related]
13. A Review of Papillary Renal Cell Carcinoma and MET Inhibitors. Rhoades Smith KE; Bilen MA Kidney Cancer; 2019 Nov; 3(3):151-161. PubMed ID: 31867475 [TBL] [Abstract][Full Text] [Related]
14. High CENPA expression in papillary renal cell carcinoma tissues is associated with poor prognosis. Li J; Li Q; Yuan Y; Xie Y; Zhang Y; Zhang R BMC Urol; 2022 Sep; 22(1):157. PubMed ID: 36163007 [TBL] [Abstract][Full Text] [Related]
15. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles. Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK Front Immunol; 2023; 14():1182581. PubMed ID: 37638025 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma. Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464 [TBL] [Abstract][Full Text] [Related]
17. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195 [TBL] [Abstract][Full Text] [Related]
18. [Clinicopathological features and prognostic analysis of papillary renal cell carcinoma]. Bo ES; Hong P; Zhang Y; Deng SH; Ge LY; Lu M; Li N; Ma LL; Zhang SD Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):615-620. PubMed ID: 35950382 [TBL] [Abstract][Full Text] [Related]
19. Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma--a multicentre study. Steffens S; Janssen M; Roos FC; Becker F; Schumacher S; Seidel C; Wegener G; Thüroff JW; Hofmann R; Stöckle M; Siemer S; Schrader M; Hartmann A; Kuczyk MA; Junker K; Schrader AJ Eur J Cancer; 2012 Oct; 48(15):2347-52. PubMed ID: 22698386 [TBL] [Abstract][Full Text] [Related]
20. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus. Kim KH; You D; Jeong IG; Kwon TW; Cho YM; Hong JH; Ahn H; Kim CS BJU Int; 2012 Dec; 110(11 Pt B):E673-8. PubMed ID: 22973869 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]